The New England journal of medicine
-
Randomized Controlled Trial Multicenter Study
A clinical trial of progesterone for severe traumatic brain injury.
Progesterone has been associated with robust positive effects in animal models of traumatic brain injury (TBI) and with clinical benefits in two phase 2 randomized, controlled trials. We investigated the efficacy and safety of progesterone in a large, prospective, phase 3 randomized clinical trial. ⋯ Primary and secondary efficacy analyses showed no clinical benefit of progesterone in patients with severe TBI. These data stand in contrast to the robust preclinical data and results of early single-center trials that provided the impetus to initiate phase 3 trials. (Funded by BHR Pharma; SYNAPSE ClinicalTrials.gov number, NCT01143064.).
-
Letter Case Reports
Remission of recalcitrant dermatomyositis treated with ruxolitinib.